Cross-Protection Against H1N1 with New Vaccines
Author Information
Author(s): Soboleski Mark R., Gabbard Jon D., Price Graeme E., Misplon Julia A., Lo Chia-Yun, Perez Daniel R., Ye Jianqiang, Tompkins S. Mark, Epstein Suzanne L.
Primary Institution: Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration
Hypothesis
Can cold-adapted and recombinant adenovirus vaccines provide cross-protective immunity against the 2009 H1N1 virus in mice?
Conclusion
Both the NP+M2-rAd and cold-adapted vaccines effectively protected mice against the pH1N1 challenge within three weeks of immunization.
Supporting Evidence
- Both vaccines protected mice from lethal challenge with a mouse-adapted strain of the 2009 pandemic H1N1 virus.
- Immunization with NP+M2-rAd resulted in high serum anti-NP IgG titers.
- Cold-adapted vaccine induced protective immunity despite the mismatch with the challenge virus.
Takeaway
Researchers tested two types of vaccines in mice to see if they could protect against a flu virus that caused a pandemic. Both vaccines worked well to keep the mice safe.
Methodology
Mice were intranasally immunized with either cold-adapted influenza viruses or recombinant adenoviruses and then challenged with a mouse-adapted pH1N1 virus.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Female BALB/c and C57BL/6 mice, aged six to eight weeks.
Statistical Information
P-Value
p≤0.05
Statistical Significance
p≤0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website